Therapeutic effect of traditional Chinese medicine on coagulation disorder and accompanying intractable jaundice in hepatitis B virus-related liver cirrhosis patients

Table 1 Balance test for general information

		Cases (n)	Sex (male/female)	Age (mean ± SD)	Days of hospitalization (mean ± SD)
Fib (1.6-2.0 g/L) level	Research group	30	20/10	49.83 ± 12.32	35.73 ± 24.20
	Control group	30	21/9	44.67 ± 10.34	36.83 ± 18.15
	P value		0.781	0.084	0.843
Fib (1.1-1.5 g/L) level	Research group	30	20/10	50.27 ± 11.71	37.10 ± 19.94
	Control group	30	19/11	49.60 ± 10.45	30.37 ± 16.81
	P value		0.787	0.817	0.128
Fib ( ≤ 1.0 g/L) level	Research group	10	7/3	46.80 ± 8.92	41.70 ± 27.57
	Control group	15	10/5	43.20 ± 10.71	54.93 ± 37.10
	P value		1.000	0.389	0.346

Anyone in the three subgroups divided by the standard Fib level, age, sex and days of hospitalization was balanced between research and control groups before treatment.

Table 2 Balance test for indexes of coagulation function before treatment (mean ± SD)

		Fib (g/L)	PT (s)	PLT (109/L)
Fib (1.6-2.0 g/L) level	Research group	1.68 ± 0.18	20.52 ± 3.12	69.07 ± 32.57
	Control group	1.72 ± 0.15	21.01 ± 3.31	83.60 ± 56.41
	P value	0.279	0.563	0.227
Fib (1.1-1.5 g/L) level	Research group	1.25 ± 0.13	22.27 ± 2.18	59.87 ± 29.90
	Control group	1.29 ± 0.11	22.60 ± 5.75	71.67 ± 24.24
	P value	0.138	0.765	0.099
Fib ( ≤ 1.0 g/L) level	Research group	0.77 ± 0.19	26.59 ± 5.39	62.80 ± 33.19
	Control group	0.79 ± 0.18	31.49 ± 8.68	73.27 ± 57.34
	P value	0.861	0.127	0.608

Anyone in the three subgroups divided by the standard Fib level and the indexes of coagulation function was balanced between research and control groups before treatment.

Table 3 Balance test for indexes of liver function before treatment (mean ± SD)

		ALT (U/L)	AST (U/L)	TBIL (μmol/L)	ALB (g/L)
Fib (1.6-2.0 g/L) level	Research group	180.90 ± 255.59	163.17 ± 176.13	104.51 ± 65.26	32.79 ± 4.69
	Control group	241.87 ± 349.01	190.87 ± 191.11	126.97 ± 61.69	33.47 ± 3.72
	P value	0.089	0.562	0.176	0.537
Fib (1.1-1.5 g/L) level	Research group	118.57 ± 121.99	144.37 ± 113.62	129.71 ± 95.70	31.74 ± 4.69
	Control group	234.07 ± 392.07	232.87 ± 265.04	169.95 ± 156.22	29.59 ± 5.54
	P value	0.129	0.098	0.234	0.111
Fib ( ≤ 1.0 g/L) level	Research group	74.40 ± 30.89	92.40 ± 78.44	198.40 ± 123.37	29.60 ± 3.82
	Control group	181.67 ± 283.59	142.80 ± 128.34	245.57 ± 193.69	30.15 ± 6.61
	P value	0.249	0.280	0.503	0.817

Anyone in the three subgroups divided by the standard of Fib level and the indexes of liver function was balanced between research and control groups before treatment.

Table 4 Balance test for related clinical materials before treatment

		Combined with ascites liquid	Combined with hepatic encephalopathy	Combined with infection	Combined with liver cancer
Fib (1.6-2.0 g/L) level	Research group	10	0	8	5
	Control group	15	3	15	2
	P value	0.190	0.236	0.063	0.421
Fib (1.1-1.5 g/L) level	Research group	17	1	10	6
	Control group	20	0	13	2
	P value	0.426	1.000	0.426	0.255
Fib ( ≤ 1.0 g/L) level	Research group	8	1	4	0
	Control group	12	1	5	1
	P value	1.000	1.000	0.734	1.000

Anyone in the three subgroups divided by standard Fib level, and clinical materials such as complications was balanced between research and control groups before treatment.

Table 5 Fib (1.6-2.0 g/L) level and serum index before and after treatment (mean ± SD)

		Fib (g/L)	PT (s)	PLT (109/L)	TBIL (μmol/L)	ALB (g/L)
Research group 30 cases	Before treatment	1.68 ± 0.18	20.52 ± 3.12	69.07 ± 32.57	104.51 ± 65.26	32.79 ± 4.69
	After treatment	1.95 ± 0.43	17.66 ± 2.38	80.10 ± 42.12	34.44 ± 17.10	36.32 ± 3.98
Control group 30 cases	Before treatment	1.72 ± 0.15	21.01 ± 3.31	83.60 ± 56.41	126.97 ± 61.69	33.47 ± 3.72
	After treatment	1.64 ± 0.44	19.07 ± 7.13	67.63 ± 42.65	113.60 ± 163.86	35.69 ± 5.21
P value		< 0.0001	< 0.0001	0.259	0.008	0.604

PT, Fib and TBIL were significantly higher in the research group than in the control group after treatment.

Table 6 Fib (1.1-1.5 g/L) level before and after treatment (mean ± SD)

		Fib (g/L)	PT (s)	PLT (109/L)	TBIL (μmol/L)	ALB (g/L)
Research group 30 cases	Before treatment	1.25 ± 0.13	22.27 ± 2.18	59.87 ± 29.90	129.71 ± 95.70	31.74 ± 4.69
	After treatment	1.72 ± 0.33	18.45 ± 2.11	59.50 ± 27.86	46.75 ± 19.83	36.46 ± 3.83
Control group 30 cases	Before treatment	1.29 ± 0.11	22.60 ± 5.75	71.67 ± 24.24	169.95 ± 156.22	29.59 ± 5.54
	After treatment	1.29 ± 0.41	20.56 ± 9.99	68.37 ± 27.20	130.95 ± 180.92	35.51 ± 4.75
P value		< 0.0001	0.032	0.217	0.014	0.399

PT, Fib and TBIL were significantly higher in the research group than in the control group after treatment.

Table 7 Fib (≤ 1.0 g/L) level before and after treatment (mean ± SD)

		Fib (g/L)	PT (s)	PLT (109/L)	TBIL (μmol/L)	ALB (g/L)
Research group 10 cases	Before treatment	0.77 ± 0.19	26.59 ± 5.39	62.80 ± 33.19	198.40 ± 123.37	29.60 ± 3.82
	After treatment	1.29 ± 0.35	23.29 ± 5.35	54.80 ± 37.42	77.85 ± 39.21	35.31 ± 5.07
Control group 10 cases	Before treatment	0.79 ± 0.18	31.49 ± 8.68	73.27 ± 57.34	245.57 ± 193.69	30.15 ± 6.61
	After treatment	0.90 ± 0.36	39.08 ± 22.78	70.93 ± 54.06	173.47 ± 149.30	35.86 ± 5.71
P value		0.013	0.043	0.421	0.061	0.807

PT and Fib were significantly higher in the research group than in the control group after treatment.